Analysis of the therapeutic effects of lung cancer at different stages. Analysis of the therapeutic effects of lung cancer at different stages.

Lung cancer is a common cancer. There are many reasons why people get lung cancer. Lung cancer causes great harm to patients, and the most serious is that it endangers the patient's life. The treatment effect of lung cancer patients at different stages is different. The following is an analysis of the treatment effect of lung cancer at different stages.

Lung cancer is a common malignant tumor. With the continuous development of industrial technology, the incidence and mortality of lung cancer have increased rapidly. The cause of lung cancer is still unclear, and it may be related to various chemical substances such as smoking and radiation. Due to the high mortality rate caused by lung cancer, we urge everyone to seek treatment as soon as possible. Taking treatment measures at different times will affect the effect of treatment.

Treatment of early stage lung cancer:

Timely surgical resection of early lung cancer can clinically cure most lung cancer patients, with five-year and ten-year survival rates reaching over 70% and 50% respectively. For some highly selected beneficiaries, postoperative adjuvant chemotherapy with two-drug platinum-containing regimens for 4-6 cycles can also improve long-term survival.

The 5-year survival rate of patients with early-stage lung cancer (stage IA-IIB) after surgery is 36%-73%. Among them, the 5-year survival rate of stage I patients is nearly 60%, and the 5-year survival rate of stage IA patients is even 73%. Therefore, a considerable number of patients with early-stage lung cancer can be cured. Therefore, health examinations are particularly important. Once early-stage lung cancer is discovered, surgery should be performed in a timely manner to strive for the possibility of cure.

Treatment of advanced lung cancer:

Patients with stage III and IV lung cancer are in the middle and late stages of lung cancer, accounting for 70-80%. Most of them have lost the opportunity for surgery and have to take comprehensive treatment with radiotherapy and chemotherapy as the main treatment. Standardized treatment can fully prolong the patient's survival time and improve the quality of life, but the 5-year survival rate is 2%-20%.

Lung cancer patients in stages III-IV are in the middle and late stages. Through regular treatment, the 5-year survival rate of patients in stage IIIA can reach 20%, but the 5-year survival rate of patients in stages IIIB-IV is only about 10%. Recently, with the emergence of a new generation of drugs, especially molecular targeted drugs, the survival rate of patients has been further improved, especially for patients with EGFR gene mutations, the efficacy will be higher, and the 2-year survival rate will even exceed 50%, bringing hope to the treatment of lung cancer.